NCT05786924 2026-04-21
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Phase 1/2 Recruiting
Servier
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Janssen Research & Development, LLC
Novartis
Hoffmann-La Roche
Bristol-Myers Squibb